MOTS - Motus GI Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.18
-0.02 (-0.38%)
As of 10:45AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.20
Open5.58
Bid5.18 x 800
Ask5.31 x 1200
Day's Range5.00 - 5.59
52 Week Range3.75 - 10.66
Volume27,941
Avg. Volume83,230
Market Cap81.214M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.49
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Motus GI Appoints Medical Device Commercial Leader Timothy P. Moran as Chief Executive Officer; Mark Pomeranz Continues in Key Executive Leadership Role as President and Chief Operating Officer

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Timothy P. Moran will assume the role of Chief Executive Officer and member of the Board of Directors on October 1, 2018. Mr. Moran will join Motus GI from ConvaTec Group Plc (CTEC.L) where he has served as President of the Americas since 2015.

  • Is Motus GI Holdings Inc’s (NASDAQ:MOTS) Balance Sheet A Threat To Its Future?
    Simply Wall St.12 days ago

    Is Motus GI Holdings Inc’s (NASDAQ:MOTS) Balance Sheet A Threat To Its Future?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Motus GI Holdings Inc (NASDAQ:MOTS), as the company does not have to adhere to strict debt covenants. However, it alsoRead More...

  • Business Wire13 days ago

    Motus GI Receives FDA Clearance to Market Pure-Vu® Slim Sleeve for Use with Slim Colonoscopes

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that it has received special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Pure-Vu® Slim Sleeve, a compatible extension to the Pure-Vu® System for slim colonoscopes.

  • Business Wirelast month

    Motus GI Reports 2018 Second Quarter Financial Results and Provides Business Update

    – Building clinical and health economic evidence demonstrating potential value of the Pure-Vu® System in high need patient populations with focus on inpatient colonoscopy market –

  • Business Wire2 months ago

    Motus GI Appoints Jeff Hutchison as VP of U.S. Sales and Commercial Operations

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today the appointment of Jeff Hutchison as Vice President of U.S. Sales and Commercial Operations. Mr. Hutchison will be responsible for building Motus GI’s U.S. sales organization and driving the Company’s pre-launch commercial activities ahead of the planned launch of the Pure-Vu® System into the inpatient market in 2019.

  • Business Wire2 months ago

    Motus GI Strengthens IP Portfolio with Issuance of Japanese Patent for the Pure-Vu® System

    Motus GI Holdings, Inc., (MOTS) (“Motus GI” or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that the Japanese Patent Office has issued a patent covering claims related to the Company’s flagship product, the Pure-Vu® System, a medical device that cleanses the colon intra-procedurally to facilitate improved visualization during a colonoscopy procedure to enable a quality exam and has demonstrated effective cleaning in hundreds of procedures. “The need to improve the quality, efficiency and cost-effectiveness of inpatient colonoscopy procedures is a global issue. While our immediate focus continues to be on market development and preparation for commercial launch of the Pure-Vu® System for inpatient colonoscopy in the U.S., we believe Japan is a key international market for future commercial expansion,” commented Mark Pomeranz, CEO of Motus GI.

  • Business Wire3 months ago

    Motus GI Announces Inclusion in the Russell Microcap® Index

    Motus GI Holdings, Inc., (MOTS) (“Motus GI” or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it was added to the Russell Microcap® Index at the conclusion of the Russell indexes annual reconstitution on June 22, 2018.

  • Business Wire4 months ago

    Motus GI Presents Cost Analysis Data Demonstrating Pure-Vu® System Has the Potential to Reduce Costs and Incidence of Colorectal Cancer at Digestive Disease Week® 2018

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes, costs and quality of care, today announced that data from a cost-minimization analysis simulating the average lifetime costs and incidence of new colorectal cancer (CRC) comparing colonoscopy using Motus GI’s Pure-Vu® System versus standard colonoscopy (SC) alone were presented by Professor Ian M. Gralnek, MD, MSHS, FASGE, at Digestive Disease Week® 2018 (“DDW”), on June 2, 2018.

  • Business Wire4 months ago

    Motus GI Enrolls First Patient in REDUCE Study of the Pure-Vu® System in Hospitalized Patients

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has enrolled the first patient in its REDUCE (Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement) study. The REDUCE study is a single-arm multi-center, prospective study that will utilize the Pure-Vu® System to facilitate bowel cleansing in approximately 100 hospitalized patients who are indicated for a diagnostic colonoscopy procedure. The Pure-Vu® System is a medical device that cleans the colon intra-procedurally to facilitate improved visualization during a colonoscopy procedure to enable a quality exam and has demonstrated effective cleaning in hundreds of procedures.

  • Business Wire4 months ago

    Motus GI Announces Issuance of Chinese Patent for the Pure-Vu® System

    Motus GI Holdings, Inc., (MOTS) (“Motus GI” or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that the Chinese Patent Office (SIPO) has granted a patent that covers the Company’s flagship product, the Pure-Vu® System. The Pure-Vu® System is a medical device that cleanses the colon during a colonoscopy procedure to facilitate improved visualization enabling a quality exam. “With colorectal cancer being one of the top three most commonly diagnosed cancers in the world, accounting for over 1.4 million new cases and 700,000 deaths, it is important that we bring the Pure-Vu® System to patients across the globe over the next several years,” said Mark Pomeranz, CEO of Motus GI.

  • Business Wire4 months ago

    Motus GI Reports 2018 First Quarter Financial Results and Provides Business Update

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today its financial results for the quarter ended March 31, 2018 and provided a business update.

  • Business Wire5 months ago

    Motus GI to Present Data at Digestive Disease Week® 2018 Showing Pure-Vu® System May Reduce Costs and Incidence of Colorectal Cancer

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that data related to the Company’s Pure-Vu® System will be presented at Digestive Disease Week® 2018 (“DDW”), being held June 2-5, 2018 in Washington, DC. The Pure-Vu® System is a medical device that cleans the colon intra-procedurally to facilitate improved visualization during a colonoscopy procedure to enable a quality exam and has demonstrated effective cleaning in hundreds of procedures.

  • Business Wire5 months ago

    Motus GI Bolsters Medical Advisory Board with Appointment of Seth A. Gross, MD, FACG, FASGE, AGAF

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has appointed Seth A.

  • Business Wire6 months ago

    Motus GI Announces 2017 Financial Results and Provides Business Outlook

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today its financial results for the year ended December 31, 2017 and provided its 2018 business outlook.

  • Business Wire6 months ago

    Motus GI Expands Intellectual Property Portfolio with New U.S. Patent Issuance for the Pure-Vu® System

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that the U.S.

  • Business Wire6 months ago

    Motus GI Announces Issuance of European Patent for the Pure-Vu® System

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that the European Patent Office has issued a patent No.

  • Business Wire6 months ago

    Motus GI to Present at the Oppenheimer 28th Annual Healthcare Conference

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that Mark Pomeranz, CEO, will present at the Oppenheimer 28th Annual Healthcare Conference in New York City on Tuesday, March 20, 2018 at 3:20 p.m.

  • Business Wire7 months ago

    Motus GI Receives CE Mark Approval for the Pure-Vu® System

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has received European CE mark approval for its flagship product, the Pure-Vu® System.

  • Marketwired7 months ago

    Motus GI Announces NASDAQ Closing Bell Ceremony

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that Mark Pomeranz, CEO of Motus, along with other members of the executive......

  • Marketwired7 months ago

    Motus GI Announces Closing of Initial Public Offering

    Motus GI Holdings, Inc., , a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today the closing of its initial public offering of 3,500,000 shares of its ...